Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 3-15

  Kormeili, T ^a   Lowe, N J ^a   Yamauchi, P S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunomodulators; Immunopathogenesis; Immunotherapy; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ASCOMYCIN; CLOBETASOL; CYCLOSPORIN; CYTOKINE; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PSORALEN; ROSIGLITAZONE; TAZAROC; TAZAROTENE;

ALLERGY; BLOOD DISEASE; CAPILLARY LEAK SYNDROME; CELLULAR IMMUNITY; CHEILITIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREAM; DEMYELINATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPIDEMIOLOGICAL DATA; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEREDITY; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; LIVER DISEASE; NAUSEA; NEUROLOGIC DISEASE; OINTMENT; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; QUALITY OF LIFE; REVIEW; RHINITIS; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMIC THERAPY; TOXICITY; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT GAIN;

BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; PSORIASIS; T-LYMPHOCYTES; UNITED STATES;

EID: 4043128142     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06009.x     Document Type: Review

References (118)

1. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999; 26: 723-33.
2. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102: 14-18S.
3. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974; 109: 207-11.
4. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6.
5. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140 (Suppl. 54): 1-7.
6. Farber EM, Nall ML. Genetics of psoriasis: twin study. In: Psoriasis: Proceedings of the International Symposium (Farber EM, Cox AJ, eds). Stanford: Stanford University Press, 1971: 7-13.
7. Elder JT, Nair RP, Guo S-W et al. The genetics of psoriasis. Arch Dermatol 1994; 130: 216-24.
8. Matthews D, Fry L, Powles A et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 1996; 14: 231-3.
9. Matthews D, Fry L, Powles A et al. Confirmation of genetic heterogeneity in familial psoriasis. J Med Genet 1995; 32: 546-8.
10. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19: 837-41.
11. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 1990; 181: 51-3.
12. Baker H. Psoriasis - clinical features. Br Med J 1971; 3: 231-3.
13. Lazarus GS, Gilgor RS. Psoriasis, polymorphonuclear leukocytes, and lithium carbonate. An important clue. Arch Dermatol 1979; 115: 1183-4.
14. Duvic M, Johnson TM, Rapini RP et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 1987; 123: 1622-32.
15. Swerlick RA, Cunningham MW, Hall NK. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. J Invest Dermatol 1986; 87: 367-71.
16. Valdimarsson H, Sigmundsdottir H, Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997; 107 (Suppl. 1): 21-4.
17. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS 2000; 14: 239-46.
18. Mallon E, Young D, Bunce M et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 1998; 139: 527-33.
19. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-6.
20. Huang BB, Bonish BK, Chaturvedi V et al. Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J Invest Dermatol 2001; 116: 305-12.
21. Bonish B, Jullien D, Dutronc Y et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000; 165: 4076-85.
22. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-94.
23. Gottlieb AB, Grossman RM, Khandke L et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992; 98: 302-9.
24. Gottlieb AB. Immunologic mechanisms in psoriasis. J Invest Dermatol 1990; 95: 18S-19S.
25. Baker BS, Swain AF, Griffiths CE et al. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol 1985; 61: 526-34.
26. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
27. Paukkonen K, Naukkarinen A, Horsmanheimo M. The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11c+ macrophages into the epidermis. Arch Dermatol Res 1992; 284: 375-9.
28. Chin YH, Falanga V, Taylor JR et al. Adherence of human helper/memory T-cell subsets to psoriatic dermal endothelium. J Invest Dermatol 1990; 94: 413-17.
29. Faure M, Thivolet J. Use of monoclonal antibodies specific for T cell subsets in cutaneous disorders: I. Quantitative analysis of peripheral blood lymphocytes. J Clin Immunol 1982; 2: 103-10S.
30. Reichrath J, Muller SM, Kerber A et al. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
31. Vandermeeren M, Janssens S, Borgers M et al. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.
32. Homey B, Dieu-Nosjean MC, Wiesenborn A et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164: 6621-32.
33. Nakamura K, Yasaka N, Asahina A et al. Increased numbers of CD68 antigen positive dendritic epidermal cells and upregulation of CLA (cutaneous lymphocyte-associated antigen) expression on these cells in various skin diseases. J Dermatol Sci 1998: 18: 170-80.
34. Jiang WY, Chattedee AD, Raychaudhuri SP et al. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001; 40: 699-703.
35. Menssen A, Trommler P, Vollmer S et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995; 155: 4078-83.
36. Szabo SK, Hammerberg C, Yoshida Y et al. Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998; 111: 1072-8.
37. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990; 126: 351-5.
38. Chaturvedi V, Qin JZ, Denning MF et al. Apoptosis in proliferating, senescent, and immortalized keratinocytes. J Biol Chem 1999; 274: 23358-67.
39. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993; 14: 69-74.
40. Partsch G, Wagner E, Leeb BF et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998; 57: 691-3.
41. Partsch G, Steiner G, Leeb BF et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
42. Partsch G, Wagner E, Leeb BF et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and SIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998; 25: 105-10.
43. De Rie MA, Zonneveld M, Witkamp L et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 1996; 76: 357-60.
44. Spadaro A, Taccari E, Riccieri V et al. Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 1996; 14: 413-16.
45. Carducci M, Mussi A, Bonifati C et al. sICAM-1, sIL-2R and beta 2-microglobulin serum levels in patients affected with psoriasis: relationship with disease severity. Arch Dermatol Res 1994; 286: 420-2.
46. Asadullah K, Docke WD, Sabat RV et al. The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin Invest Drugs 2000; 9: 95-102.
47. Kang S, Yi S, Griffiths CE et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138: 77-83.
48. Olaniran AK, Baker BS, Paige DG et al. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996; 288: 421-5.
49. Mussi A, Bonifati C, Carducci M et al. IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents 1994; 8: 117-20.
50. Uyemura K, Yamamura M, Fivenson DF et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
51. Damle NK, Klussman K, Linsley PS et al. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 1992; 148: 1985-92.
52. Conrad P, Rothman BL, Kelley KA, Blue ML. Mechanism of peripheral T cell activation by coengagement of CD44 and CD2. J Immunol 1992; 149: 1833-9.
53. De Rie MA, Van Cairo I, Lier RA, Bos JD. Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skin. Clin Exp Dermatol 1996; 21: 104-11.
54. Kaplon RJ, Hochman PS, Michler RE et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356-63.
55. Krueger GG, Papp KA, Stough DB et al. A, randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
56. Lowe NJ, Gonzalez J, Bagel J et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003; 42: 224-30.
57. Lebwohl M, Christophers E, Langley R et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
58. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related qualify of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4: 131-9.
59. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307-15.
60. Koo J, Rizova E, Freedman D et al. Combination therapy with alefacept and ultraviolet B light for treatment of psoriasis. Program of the 61st Annual Meeting of the American Academy of Dermatology, 22-26 March 2003; San Francisco, CA, U.S.A., Poster 607.
61. Efalizumab. Anti-CD11a monoclonal antibody - Genentech/Xoma, HU 1124, hu1124, xanelim. Drugs R D 2002; 3: 40-3.
62. Blazar BR, Taylor PA, Panoskaltsis-Mortari A et al. Coblockade of the LFA1: ICAM and CD28/CTLA4: B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995; 85: 2607-18.
63. Pandolfi F, Trentin L, Boyle LA et al. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer 1992; 69: 1165-73.
64. Simmons DL. The role of ICAM expression in immunity and disease. Cancer Surv 1995; 24: 141-55.
65. Wei L, Debets R, Hegmans JJ et al. IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production. J Pathol 1999; 187: 358-64.
66. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-74.
67. Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-35.
68. Lebwohl M, Tyring SK, Hamilton TK et al. The Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
69. Cather JC, Cather JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3: 361-70.
70. Gottlieb AB, Miller B, Lowe NJ et al. Subcutaneously administered efalizumab (anti-CD 11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003; Apr 30 (Epub ahead of print).
71. Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med 1999; 66: 367-74.
72. Goldenberg MM. Etancercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999; 21: 75-87.
73. Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999; 26 (Suppl. 57): 22-8.
74. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 57: 7-15.
75. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38: 241-51.
76. Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-7.
77. Mussi A, Bonifati C, Carducci M et al. Serum TNF-alpha levels correlate with disease activity and are reduced by effective therapy in plaque type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-18.
78. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
79. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385-90.
80. Girolomoni G, Abeni D. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 2001; 137: 784-5.
81. Zabraniecki L, Fournie B. TNF alpha inhibition in psoriatic arthritis: cause for hope. Joint Bone Spine 2001; 68: 106-8.
82. Kurschat P, Rubbert A, Poswig A et al. Treatment of psoriatic arthritis with etanercept. J Am Acad Dermatol 2001; 44: 1052.
83. ElKayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept. Ann Rheum Dis 2000; 59: 839.
84. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732-4.
85. Aboulafia DM, Bundow D, Wilske K et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093-8.
86. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118-21.
87. Gottlieb AB, Lowe NJ, Matheson RT et al. Efficacy of etanercept in patients with psoriasis. Presented at the American Academy of Dermatology, New Orleans, LA, U.S.A. 22-27 February 2002.
88. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2012-20.
89. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
90. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885-8.
91. Kwon HJ, Cote TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
92. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
93. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
94. Targan SR, van Hanauer SB, Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
95. Van Dullemen HM, Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
96. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
97. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-30.
98. Kirby B, Marsland AM, Carmichael AJ et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27-9.
99. Ogilvie AL, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-9.
100. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002; 138: 644-8.
101. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003; 44: 116-20.
102. Schopf RE, Aust H, Knop J. Treatment of psoriasis with chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-91.
103. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68-75.
104. Gottlieb AB, Chaudhari U, Mulcahy LD et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-35.
105. Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002; 20: S122-5.
106. Al-Salem IH. Striking and rapid improvement of plaque psoriasis with infliximab. A report of two cases. Dermatology 2003; 207: 54-6.
107. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73.
108. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
109. Van Leent EJ, Ebelin ME, Burtin P et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), (SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204: 63-8.
110. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-6.
111. Wolff K. Oral pimecrolimus effective in treating psoriasis. Program of the 61st Annual Meeting of the American Academy of Dermatology, 24 March 2003; San Francisco, CA, U.S.A.
112. SmithKline Beecham Pharmaceuticals. Prescribing Information for Avandia (Rosiglitazone Maleate) AV.L2. Philadelphia: SmithKline Beecham Pharmaceuticals. 1999.
113. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
114. Vamecq J, Latruffe N. Medical significance of peroxisome proliferators-activated receptors. Lancet 1999; 354: 141-8.
115. Ellis C, Varani J, Fisher G et al. Troglitazone improves psoriasis and normalizes modes of proliferative skin disease. Arch Dermatol 2000; 136: 609-16.
116. Pershadsingh HA, Sproul JA, Benjamin E et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134: 1304-5.
117. Girard J. Mechanisms of action of thazolidinediones. Diabetes Metab 2001; 27: 271-8.
118. Yamauchi PS, Rizk D, Kormeili T, Lowe NJ. Systemic retinoids. In: Therapy of Moderate-to-Severe Psoriasis (Weinstein GD, Gottlieb AB. eds), 2nd edn. New York; National Psoriasis Foundation, Marcel Dekker Inc., 2003; 137-50.